Wells Fargo & Company Vor Biopharma Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.8 - $2.85 $3,382 - $5,355	1,879 Added 16.18%	13,489 $31,000
Q4 2023 Feb 09, 2024	BUY	$1.66 - $2.63 $3,804 - $6,027	2,292 Added 24.6%	11,610 $26,000
Q3 2023 Nov 13, 2023	SELL	$2.1 - $3.35 $10,502 - $16,753	-5,001 Reduced 34.93%	9,318 $19,000
Q2 2023 Aug 15, 2023	BUY	$3.09 - $5.33 $43,559 - $75,137	14,097 Added 6350.0%	14,319 $44,000
Q1 2023 May 12, 2023	BUY	$4.68 - $6.96 $496 - $737	106 Added 91.38%	222 $1,000
Q4 2022 Feb 13, 2023	BUY	$3.77 - $7.43 $22 - $44	6 Added 5.45%	116 $0
Q3 2022 Nov 14, 2022	BUY	$3.9 - $5.52 $156 - $220	40 Added 57.14%	110 $0
Q2 2022 Aug 12, 2022	SELL	$3.89 - $6.44 $1,380 - $2,286	-355 Reduced 83.53%	70 $0
Q1 2022 May 16, 2022	SELL	$6.04 - $12.23 $40,733 - $82,479	-6,744 Reduced 94.07%	425 $3,000
Q4 2021 Feb 14, 2022	BUY	$11.32 - $18.02 $80,813 - $128,644	7,139 Added 23796.67%	7,169 $83,000
Q3 2021 Nov 15, 2021	SELL	$12.24 - $20.38 $722 - $1,202	-59 Reduced 66.29%	30 $0
Q2 2021 Aug 16, 2021	SELL	$18.65 - $38.78 $64,715 - $134,566	-3,470 Reduced 97.5%	89 $2,000
Q1 2021 May 13, 2021	BUY	$30.96 - $54.08 $110,186 - $192,470	3,559 New	3,559 $153,000

47.9M

1.5K

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $24.4M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.